poziotinib,tucatinib,trastuzumab,margetuximab,ruxolitinib,pertuzumab,lapatinib,rivoceranib
macrogenics,roche,jiangsu hengrui medicine,zai lab,incyte,elevar therapeutics,spectrum pharmaceuticals,novartis,luye pharma group,seagen
[]
anti her2 therapy for gastric and ge junction cancer increasing. #ascogi23 #gi23 
Oncology care , to give or not to give chemo , data analysis , oncology pharamocovigilance , enthusiastic critic, twitts are not twists